Inogen INGN
INGN's growth narrative rests on an inflated $3-4B TAM that Medicare data contradicts; under a realistic 1.3M-user market, peak unit sales arrive this year or next.
Thesis
Muddy Waters' February 25, 2019 follow-up presses Inogen management to defend the TAM claims at the heart of its growth story, after INGN remained silent during its quiet period following the February 8 initial short report. Carson Block argues the company's $3-4B U.S. oxygen-therapy TAM cannot be reconciled with Medicare's $740M of 2017 oxygen spending and INGN's own disclosure that Medicare represents 60% of patients, which implies a true market of only ~$1.2B. Using Kaiser Family Foundation data, Muddy Waters calculates the patient base is shrinking at a -2.6% CAGR rather than growing 7-10% as INGN previously asserted. Combined with insider sales exceeding $145M since IPO and the quiet removal of WinterGreen Research citations, the firm models INGN reaching peak steady-state U.S. unit sales of roughly 176,696 units this year or next.
SCQA
Inogen sells portable oxygen concentrators directly to consumers and through B2B channels, telling investors it is penetrating a $3-4B U.S. oxygen-therapy market growing 7-10% annually.
Medicare data, INGN's own 60% patient mix disclosure, and Kaiser Family Foundation Advantage figures imply a market of only ~$1.2B that is shrinking at -2.6% CAGR, while management quietly deleted prior growth claims and WinterGreen citations.
Management must publicly answer six specific questions on the next earnings call, explaining the $1.8-2.8B TAM gap, market-growth methodology, removed citations, and whether peak unit sales arrive this year or next.
Honest answers would force a rerating: under a 1.3M-user TAM, INGN reaches peak steady-state U.S. unit sales of ~176,696, capping the growth story that supports the multiple and validating the short.
The three reasons
- 1
Claimed $3-4B TAM implies $1.8-2.8B unexplained gap vs. Medicare data
- 2
Patients on oxygen therapy declining at -2.6% CAGR, not growing as INGN claims
- 3
Insiders sold over $145M of stock since IPO; credibility hinges on transparent answers
Primary demands
- Management must answer six specific questions on the upcoming earnings call regarding TAM size and methodology
- Reconcile the $1.8B-$2.8B gap between claimed $3-4B TAM and Medicare-implied $1.2B market
- Explain why WinterGreen Research citations and the 7-10% market growth claim were quietly removed from presentations
- Address whether INGN hits peak unit sales this year or next under a 1.3M-user TAM
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (2)
Notes
Three-page follow-up note to Muddy Waters' Feb 8, 2019 initial INGN short report. Page 1 is boilerplate Terms of Use; pages 2-3 contain the actual content — six pointed questions for management plus a peak-unit-sales model table on p.3. Format is a Word-style memo with the Muddy Waters Capital letterhead, no slides or charts. Authored by Carson C. Block (Director of Research). Rhetoric centers on management's silence during the quiet period and the quiet removal of WinterGreen citations and the 7-10% growth claim, used as quote-contradiction signals. No stake disclosed, no price target, no peer benchmarking. Classified as research_note + follow_up given it explicitly references and builds on the Feb 8 initial report.